We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Iceni Pharmaceuticals Launches as New Company

Iceni Pharmaceuticals Launches as New Company

Iceni Pharmaceuticals Launches as New Company

Iceni Pharmaceuticals Launches as New Company

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Iceni Pharmaceuticals Launches as New Company"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Iceni Pharmaceuticals has announced its launch as a new company, focusing on developing repurposed and reformulated cancer therapies. The company’s lead product Cilcane® (generic name cilengitide) is being repurposed by Iceni as a first-in-class treatment for multiple myeloma. Iceni has demonstrated in pre-clinical studies that Cilcane® is effective as a combination therapy when given with proteasome inhibitors such as bortezomib, and that this approach may also be applicable to breast and other cancers.

Iceni has a broad intellectual property portfolio covering the formulation and methods of use of Cilcane®. Cilengitide was formerly in late-stage clinical trials in glioblastoma with Merck Serono. Iceni Pharmaceuticals is planning a Phase II safety/efficacy trial of Cilcane® starting in 2017 aimed at relapsed refractory patients who have already received one prior therapy of proteasome inhibitor. The Company has appointed several leading authorities on cilengitide and multiple myeloma to its scientific advisory board, including:

• Annalisa Jenkins, previously Head of Global Research & Development at Merck Serono, during the time cilengitide was in development.
• Dr Bruno Osterwalder, previously Senior VP (Oncology) at Merck Serono.
• Gareth Morgan, MD, PhD, FRCP, FRCPath, professor of medicine and pathology and director of the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences (UAMS), one of the world’s foremost myeloma treatment centres.
• Dr Horst Kessler, Munich Technical University, and a named inventor of cilengitide.

Dr John March, CEO at Iceni Pharmaceuticals, commented: “We are excited by the prospect of repurposing cilengitide as a novel combination therapy for the treatment of multiple myeloma and building on its established safety profile to improve the clinical outcome and quality of life of patients. Our prestigious team of world renowned scientific advisors are testament to the belief in the product and its potential.”